A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
You are here: Home / Top Stories / Dow Jones Newswires: FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics